Approval · Notice of Compliance 35709 · 2025
ALYFTREK: Notice of Compliance 35709
Issued July 21, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35709
- Date
- July 21, 2025
- Company
- Vertex Pharmaceuticals (Canada) IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- TEZACAFTOR 50 MG per TAB
- DEUTIVACAFTOR 125 MG per TAB
- VANZACAFTOR CALCIUM 10 MG per TAB
- TEZACAFTOR 20 MG per TAB
- DEUTIVACAFTOR 50 MG per TAB
- VANZACAFTOR CALCIUM 4 MG per TAB